^
Association details:
| Biomarker: | MCAM expression |
|---|---|
| Cancer: | Melanoma |
| Drug: | AMT-253 (CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma
Published date:
09/05/2023
Excerpt:
AMT-253 exhibited MUC18-specific cytotoxicity through DNA damage and apoptosis and a strong bystander killing effect, leading to potent antitumor activities against melanoma cell line and patient-derived xenograft models….Combination therapy of AMT-253 with an anti-angiogenic agent generated higher efficacy than single agent in a mucosal melanoma model. Beyond melanoma, AMT-253 was also efficacious in a wide range of MUC18-expressing solid tumors.
DOI:
https://doi.org/10.1158/0008-5472.CAN-23-1356
